---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-277136"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:14:45.192981+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD reports Q3 net loss $1.4M; evaluates strategic alternatives

## Summary
- Net loss from continuing ops $1.4M ($0.13/share) vs $14.6M ($1.58) in Q3 2022.
- License and service revenue negative $0.1M; gross royalties $1.2M for quarter.
- Operating expenses fell 88.2% to $1.7M on transition to royalty-based model.
- Board evaluating strategic alternatives including M&A, sale, or other transaction.

## SEC filing metadata
- accession: 0001193125-23-277136
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312523277136/0001193125-23-277136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312523277136/d309650d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-277136
- JSON: https://secwatch.observer/filing/0001193125-23-277136.json
- Plain text: https://secwatch.observer/filing/0001193125-23-277136.txt

## Key facts
- Earnings Releases
  TherapeuticsMD, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss from continuing operations was $1.4 million for the quarter ended September 30, 2023, or $0.13 per basic and di, EPS $0.13 per basic and diluted common share.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss from continuing operations was $1.4 million for the quarter ended September 30, 2023, or $0.13 per basic and di
  - EPS: $0.13 per basic and diluted common share
  - Result: reported results
  source text: TherapeuticsMD Announces Third Quarter 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523277136/0001193125-23-277136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.